Phaarmasia Ltd

AGM Details

• Date and mode: 25 September 2026, via VC/OAVM.
• Cut-off date: 18 September 2026; record shareholders: 20,364.
• Scrutinizer appointed for e-voting: NVSS Suryanarayana Rao.

Resolutions

• Item 1 (Ordinary): Adopt audited financial statements for year ended 31 March 2026.
• Item 2 (Ordinary): Reappointment of Rashmi Vinay Sapte as director, retiring by rotation.
• Item 3 (Ordinary): Approval of related party transactions.
• Item 4 (Ordinary): Increase in remuneration of Whole-Time Director Yallapragada Naga Bhaskara Rao.

Voting Results

• Item 1: Passed; in favour ~99.99%, against ~0.01%.
• Item 2: Passed; in favour ~99.99%, against ~0.01%.
• Item 3: Passed; related party transactions approved; in favour ~99.99%.
• Item 4: Passed; remuneration increase approved; in favour ~99.999%.

Director Changes

• Rashmi Vinay Sapte reappointed as director.
• Remuneration increase approved for Whole-Time Director Yallapragada Naga Bhaskara Rao.

Phaarmasia Ltd: Trading window closure from October 01, 2026 until 48 hours after the declaration of unaudited results for the quarter and half year ended September 30, 2026.

AGM Details

• AGM held on 25 September 2026 at 4:00 P.M. via VC/OAVM.
• Ended at 4:25 P.M.

Key Resolutions

• Adopt Audited Financial Statements for year ended 31 March 2026.
• Reappoint Rashmi Vinay Sapte as director on rotation.
• Approve related party transactions.
• Increase remuneration of Whole-Time Director Naga Bhaskara Rao Yallapragada.

Voting Status

• Voting results to be declared after Scrutinizer's report.

Financial performance

• Revenue from operations: 4720.75 Lakhs in FY2025-26, up from 2436.88.
• Total income: 4816.88 Lakhs; expenses: 4576.80.
• Profit after tax: 1757.28 Lakhs; swung from prior loss.
• Earnings per share: Rs 25.74 (basic and diluted).
• Net cash from operating activities: 2156.30 Lakhs.
• Liquidity: Current ratio 3.46; gearing ratio 0.04.
• Debt/equity ratio: 5.08; net worth 2209.68 Lakhs.
• Exceptional item: sale of land/building, profit Rs 1,878.70 Lakhs.
• Dividend: no dividend declared or recommended.

Operations & capacity

• Core products: Hormonal OCPs and Combipack with Iron.
• Annual capacity: over 30 million units.
• Geography: India-centric; export sales 119.04 Lakhs.
• Inventories: total 436.32 Lakhs at 31 Mar 2026.

Capital structure & liquidity

• Equity capital: Rs 682.70 Lakhs; authorised capital: Rs 10 Crores.
• Issued equity shares: 6,826,960.
• Net debt: 80.25 Lakhs; cash/bank balances total 1,098.50 Lakhs.
• Current assets: 2,673.60 Lakhs; current liabilities: 771.83 Lakhs.

Governance & compliance

• Board: 6 directors; 1 Executive, 3 Non-Executive, 2 Independent.
• Statutory auditors: M/s Sathuluri & Co; Secretarial auditor: N.V.S.S. Suryanarayana Rao.
• Internal audit by Oruganti & Associates; re-appointed for FY2025-26.
• Secretarial audit notes: website update pending; SOP fines paid; clarifications submitted.

Related party transactions

• RPT cap: up to Rs 100 Crores for 2026-27.
• Related parties: Maneesh Pharmaceuticals Ltd; Svizera Health Private Limited; Shub Pharma Agency.
• Maneesh Pharmaceuticals: Purchases 2,082.82 Lakhs; Sales 500.89 Lakhs.
• Svizera Health: Sales 167.83 Lakhs; Purchases 0 Lakhs.
• Shub Pharma Agency: Services 52.19 Lakhs.

Associates & subsidiaries

• Associates: Maneesh Pharmaceuticals Limited (44.22%), Svizera Labs Private Limited (29.30%).
• No subsidiary companies.

Outlook & risks

• Outlook: profitability to be sustained with growth opportunities.
• Risks: regulatory changes, cost volatility, competitive pressures.

AGM Details

• 45th AGM to be held on 25 September 2026 at 04:00 PM via VC & OAVM.
• E-voting window: 22 September 2026 09:00 AM to 24 September 2026 05:00 PM.
• Cut-off date for voting eligibility: 18 September 2026.
• Notice and annual report for FY 2025-26 hosted on company website.
• Scrip code: 523620.

Financial results (quarter ended 30 Jun 2026)

• Revenue from operations: 828.33 lakh; other income: 30.13 lakh.
• Total income: 858.46 lakh for quarter ended 30 June 2026.
• Total expenses: 826.02 lakh.
• Net profit for the quarter: 33.90 lakh.
• Basic EPS: 0.50; Diluted EPS: (1.03) Rs.
• Board approved the unaudited results on 13 August 2026.
• Single-segment operations; segment reporting not applicable.
• Auditors conducted a limited review; report placed before the board.

Results update

• Board approved Q1 2026-27 results for quarter ended 30 June 2026.
• Meeting held on 13 August 2026; results attached and filed.
• Independent auditor's review report states no material misstatement.